Author

Dhaval Desai

Institution: Astellas Pharma (United States)

Observed institution: Astellas Pharma (United States)

OpenAlex ID: A5022201779

Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

2023 · Arshad M Khanani, Sunil S Patel, et al. · The Lancet · 391

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial

2023 · Sunil S. Patel, David R. Lally, et al. · Eye · 160

Complement cascade inhibition in geographic atrophy: a review

2022 · Dhaval Desai, Pravin U. Dugel · Eye · 78

Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy

2024 · Carl J. Danzig, Arshad M. Khanani, et al. · Ophthalmology Retina · 25

Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration

2025 · Arshad M. Khanani, Carl J. Danzig, et al. · Ophthalmology · 15

Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial

2023 · Sunil S. Patel, David R. Lally, et al. · Eye · 15

Progression to complete retinal pigment epithelium and outer retinal atrophy (cRORA): post hoc analysis of the GATHER1 trial

2024 · Giulia Corradetti, Ayesha Karamat, et al. · Graefe s Archive for Clinical and Experimental Ophthalmology · 13

Safety and tolerability of avacincaptad pegol in combination with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration: results from a phase 1 and phase 2a study

2026 · Sunil S Patel, David S Boyer, et al. · BMJ Open Ophthalmology · 2

Works count: 8

Citation count: 699

H-index: 7

I10-index: 7